Topics
Gliomas | Treatment | Targeted therapy | Dabrafenib
Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > Dabrafenib
Lei J, Liu Y, Fan Y.
The effects of
dabrafenib and/or trametinib treatment in Braf V600-mutant glioma:
a systematic review and meta-analysis.
Neurosurg
Rev. 2024 Aug 22;47(1):458. doi:
10.1007/s10143-024-02664-x. PMID:
39172230. Review; Meta-analysis. ˍ
Chellapandian H, Jeyachandran S.
Letter
to Editor, "The effects of dabrafenib and/or trametinib
treatment in Braf V600mutant glioma: a systematic review and
metaanalysis".
Neurosurg
Rev. 2024 Sep 14;47(1):613. doi:
10.1007/s10143-024-02858-3. PMID:
39271502. Review; Meta-analysis˰
ˍ
Hajikarimloo B, Habibi MA, Kooshki A, Alvani MS, Zare AH,
Hasanzade A, Zare AH, Akhlaghpasand M, Tavanaei R, Tos
SM.
Dabrafenib plus trametinib in
low-grade versus high-grade gliomas: a systematic review and
meta-analysis.
BMC
Cancer. 2024 Nov 29;24(1):1473. doi:
10.1186/s12885-024-13229-y. PMID:
39614165. Review; Meta-analysis. ˍ
Hajikarimloo B, Tos SM, Alvani MS, Kooshki A, Hasanzade A, Zare
AH, Zare AH, Najari D, Habibi MA.
Efficacy
and safety of dabrafenib plus trametinib in pediatric versus adult
gliomas: a systematic review and meta-analysis.
Childs
Nerv Syst. 2025 Feb 4;41(1):104. doi:
10.1007/s00381-025-06760-1. PMID:
39904910. Review; Meta-analysis˰
ˍ
Haj Mohammad SF, Spiekman IAC, Verkerk K, Verbeek FAJ, Timmer H,
van Maren MA, Zeverijn LJ, Geurts BS, Daletzakis A, Roepman P,
Jansen AML, de Leng WWJ, Maas SLN, de Vos FYFL, Verheul HMW, Voest
EE, Gelderblom H.
BRAFV600E-mutated
central nervous system tumors benefit from treatment with
dabrafenib plus trametinib: Results from the Drug Rediscovery
Protocol.
Eur
J Cancer. 2026 Mar 11;238:116674. doi:
10.1016/j.ejca.2026.116674. PMID:
41830662. ˍ